Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.
Mau-Ern PohSivasubramaniam BalakrishnanSin Nee TanMuhammad Adil Zainal AbidinChong Kin LiamJiunn Liang TanYong Kek PangArvindran AlagaLye Mun ThoSoon Hin HowPublished in: Translational lung cancer research (2024)
-mutated advanced NSCLC patients who failed first-line treatment with first- or second-generation EGFR TKIs due to T790M mutation.